Prof Sherene Loi
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
787 Scholarly works
42 Projects
HIGHLIGHTS
2026
Journal article
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.
DOI: 10.1016/j.annonc.2026.05.7072026
Journal article
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.
DOI: 10.1038/s41523-026-00971-82026
Research grants (ARC, NHMRC, MRFF)
Innovating in Breast Cancer Immunology Treatment and Prevention
2022
Journal article
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
DOI: 10.1038/s43018-022-00413-x2021
Journal article
Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
DOI: 10.1093/jnci/djab1112018
Research Grant
Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
2018
Research grants (other domestic)
2018 NBCF Endowed Chair Program
RECENT SCHOLARLY WORKS
2026
Journal article
Giredestrant (GIRE) palbociclib (PALBO) vs letrozole (LET) PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER , HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.
DOI: 10.1200/jco.2026.44.17_suppl.lba10062026
Journal article
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1 metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.
DOI: 10.1200/jco.2026.44.17_suppl.lba10002026
Journal article
Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.
DOI: 10.1200/jco.2026.44.16_suppl.5542026
Journal article
ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) pembrolizumab (pembro) vs chemotherapy (chemo) pembro in participants (pts) with previously untreated PD-L1 metastatic triple-negative breast cancer (mTNBC).
DOI: 10.1200/jco.2026.44.16_suppl.10132026
Journal article
Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER , HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
DOI: 10.1200/jco.2026.44.16_suppl.5022026
Journal article
Trastuzumab deruxtecan (T-DXd) durvalumab (D) in patients (pts) with previously untreated HER2 unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.
DOI: 10.1200/JCO.2026.44.16_suppl.10122026
Journal article
Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) nonsteroidal aromatase inhibitor (NSAI) in HR /HER2− early breast cancer (EBC).
DOI: 10.1200/jco.2026.44.16_suppl.5012026
Journal article
Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR ), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) palbociclib (PALBO) fulvestrant (FULV).
DOI: 10.1200/jco.2026.44.16_suppl.1079